• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型抗病毒药物法匹拉韦（T-705）治疗发热伴血小板减少综合征（SFTS）。

Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705).

机构信息

Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, 8 Jingshun East Street, Chaoyang District, 100015, Beijing, People's Republic of China.

Cancer Center, Beijing Ditan Hospital, Capital Medical University, 8 Jingshun East Street, Chaoyang District, 100015, Beijing, People's Republic of China.

出版信息

Infection. 2020 Apr;48(2):295-298. doi: 10.1007/s15010-019-01364-9. Epub 2019 Oct 31.

DOI:10.1007/s15010-019-01364-9
PMID:31673977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7223615/
Abstract

BACKGROUND

Severe fever and thrombocytopenia syndrome (SFTS) is an acute illness with a high mortality (16.2-29.1%). Unfortunately, there is no specific cure or vaccine for SFTS.

METHODS

In this open-label study, two patients with SFTS were treated with favipiravir, a new antiviral drug.

RESULTS

Patients had a sustainable virologic, immunologic and symptomatic recovery.

CONCLUSIONS

Favipiravir may be a prosiming drug for the treatment of SFTS.

摘要

背景

严重发热伴血小板减少综合征（SFTS）是一种具有高死亡率（16.2-29.1%）的急性疾病。不幸的是，目前还没有针对 SFTS 的特效疗法或疫苗。

方法

在这项开放性标签研究中，两名 SFTS 患者接受了一种新型抗病毒药物——利巴韦林的治疗。

结果

患者的病毒学、免疫学和症状均得到持续恢复。

结论

利巴韦林可能是治疗 SFTS 的一种有前景的药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/7223615/d5a83f185fd7/15010_2019_1364_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/7223615/d5a83f185fd7/15010_2019_1364_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8498/7223615/d5a83f185fd7/15010_2019_1364_Fig1_HTML.jpg

相似文献

1
Severe fever with thrombocytopenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705).新型抗病毒药物法匹拉韦（T-705）治疗发热伴血小板减少综合征（SFTS）。
Infection. 2020 Apr;48(2):295-298. doi: 10.1007/s15010-019-01364-9. Epub 2019 Oct 31.
2
Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy.严重发热伴血小板减少综合征的病理生理学及特异性抗病毒治疗的进展
J Infect Chemother. 2018 Oct;24(10):773-781. doi: 10.1016/j.jiac.2018.07.009. Epub 2018 Aug 8.
3
Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir.叙利亚金黄地鼠中严重发热伴血小板减少综合征病毒感染的建模：STAT2在预防疾病中的重要性及法匹拉韦的有效治疗作用
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.01942-16. Print 2017 Feb 1.
4
A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome.一项多中心非随机、非对照、单臂临床试验，评估使用法匹拉韦治疗伴有发热伴血小板减少综合征的患者的疗效和安全性。
PLoS Negl Trop Dis. 2021 Feb 22;15(2):e0009103. doi: 10.1371/journal.pntd.0009103. eCollection 2021 Feb.
5
Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors.抗病毒检测系统的建立及严重发热伴血小板减少综合征病毒抑制剂的鉴定。
Antivir Chem Chemother. 2017 Dec;25(3):83-89. doi: 10.1177/2040206617740303. Epub 2017 Nov 3.
6
[Severe fever with thrombocytopenia syndrome: epidemiology, pathophysiology, and development of specific treatment and prevention measures].[严重发热伴血小板减少综合征：流行病学、病理生理学及特异性治疗与预防措施的进展]
Rinsho Ketsueki. 2018;59(10):2255-2259. doi: 10.11406/rinketsu.59.2255.
7
Clinical efficacy and safety evaluation of favipiravir in treating patients with severe fever with thrombocytopenia syndrome.法维拉韦治疗发热伴血小板减少综合征患者的临床疗效及安全性评价。
EBioMedicine. 2021 Oct;72:103591. doi: 10.1016/j.ebiom.2021.103591. Epub 2021 Sep 23.
8
Recent Advances in the Study of the Immune Escape Mechanism of SFTSV and Its Therapeutic Agents.近年来，发热伴血小板减少综合征布尼亚病毒（SFTSV）免疫逃避机制及其治疗药物的研究进展。
Viruses. 2023 Apr 10;15(4):940. doi: 10.3390/v15040940.
9
CD8 T cells mediate antiviral response in severe fever with thrombocytopenia syndrome.CD8 T 细胞在发热伴血小板减少综合征中介导抗病毒反应。
FASEB J. 2023 Jan;37(1):e22722. doi: 10.1096/fj.202201343RR.
10
Characterization of clinical features and outcome for human-to-human transmitted severe fever with thrombocytopenia syndrome.人传人发热伴血小板减少综合征的临床特征和结局分析。
Infect Dis (Lond). 2018 Aug;50(8):601-608. doi: 10.1080/23744235.2018.1449962. Epub 2018 Mar 15.

引用本文的文献

1
Trends in the incidence of severe fever with thrombocytopenia syndrome in Japan: an observational study from 2013 to 2022.日本重症发热伴血小板减少综合征发病率的趋势：一项2013年至2022年的观察性研究。
Sci Rep. 2025 Jul 1;15(1):20715. doi: 10.1038/s41598-025-07955-x.
2
Case Report: Successful treatment of severe fever with thrombocytopenia syndrome associated with hemophagocytic lymphohistiocytosis by preemptively using favipiravir and methylprednisolone.病例报告：通过抢先使用法匹拉韦和甲泼尼龙成功治疗与噬血细胞性淋巴组织细胞增生症相关的严重发热伴血小板减少综合征
Front Med (Lausanne). 2025 Jun 13;12:1566719. doi: 10.3389/fmed.2025.1566719. eCollection 2025.
3

本文引用的文献

1
Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011-17: a prospective observational study.中国 2011-2017 年实验室诊断的严重发热伴血小板减少综合征的流行病学和临床特征：一项前瞻性观察研究。
Lancet Infect Dis. 2018 Oct;18(10):1127-1137. doi: 10.1016/S1473-3099(18)30293-7. Epub 2018 Jul 24.
2
Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice.法匹拉韦（T-705）而非利巴韦林可有效抑制两种不同株系的克里米亚-刚果出血热病毒在小鼠体内的复制。
Antiviral Res. 2018 Sep;157:18-26. doi: 10.1016/j.antiviral.2018.06.013. Epub 2018 Jun 21.
3
Evolving therapeutic strategies for severe fever with thrombocytopenia syndrome: from past to future.
发热伴血小板减少综合征的治疗策略演变：从过去到未来
Ther Adv Infect Dis. 2025 May 16;12:20499361251340786. doi: 10.1177/20499361251340786. eCollection 2025 Jan-Dec.
4
Severe fever with thrombocytopenia syndrome (SFTS) in Thailand: using a one health approach to respond to novel zoonosis and its implications in clinical practice.泰国的严重发热伴血小板减少综合征（SFTS）：采用一体化健康方法应对新型人畜共患病及其在临床实践中的意义
One Health Outlook. 2024 Oct 1;6(1):18. doi: 10.1186/s42522-024-00112-w.
5
Epidemiology, clinical characteristics, and treatment of severe fever with thrombocytopenia syndrome.发热伴血小板减少综合征的流行病学、临床特征及治疗
Infect Med (Beijing). 2022 Jan 1;1(1):40-49. doi: 10.1016/j.imj.2021.10.001. eCollection 2022 Mar.
6
Recent Advances in the Study of the Immune Escape Mechanism of SFTSV and Its Therapeutic Agents.近年来，发热伴血小板减少综合征布尼亚病毒（SFTSV）免疫逃避机制及其治疗药物的研究进展。
Viruses. 2023 Apr 10;15(4):940. doi: 10.3390/v15040940.
7
Acute thrombocytopenia induced by trastuzumab due to complement reaction: A case report.曲妥珠单抗因补体反应导致的急性血小板减少症：一例报告。
Front Med (Lausanne). 2022 Dec 6;9:1037493. doi: 10.3389/fmed.2022.1037493. eCollection 2022.
8
Antiviral Treatment Options for Severe Fever with Thrombocytopenia Syndrome Infections.严重发热伴血小板减少综合征感染的抗病毒治疗方案
Infect Dis Ther. 2022 Oct;11(5):1805-1819. doi: 10.1007/s40121-022-00693-x. Epub 2022 Sep 22.
9
Exploration of immunological responses underpinning severe fever with thrombocytopenia syndrome virus infection reveals IL-6 as a therapeutic target in an immunocompromised mouse model.对严重发热伴血小板减少综合征病毒感染所引发免疫反应的探索揭示，在免疫受损小鼠模型中，白细胞介素-6是一个治疗靶点。
PNAS Nexus. 2022 Mar 10;1(1):pgac024. doi: 10.1093/pnasnexus/pgac024. eCollection 2022 Mar.
10
Risk Factors of Neurological Complications in Severe Fever Patients with Thrombolytic Syndrome: A Single-Center Retrospective Study in China.中国溶栓综合征严重发热患者神经系统并发症的危险因素：一项单中心回顾性研究。
Med Sci Monit. 2021 Nov 8;27:e932836. doi: 10.12659/MSM.932836.
Molecular genomic characterization of tick- and human-derived severe fever with thrombocytopenia syndrome virus isolates from South Korea.
来自韩国的蜱传和人源严重发热伴血小板减少综合征病毒分离株的分子基因组特征
PLoS Negl Trop Dis. 2017 Sep 22;11(9):e0005893. doi: 10.1371/journal.pntd.0005893. eCollection 2017 Sep.
4
Current status of severe fever with thrombocytopenia syndrome in China.中国发热伴血小板减少综合征的现状。
Virol Sin. 2017 Feb;32(1):51-62. doi: 10.1007/s12250-016-3931-1. Epub 2017 Feb 27.
5
Modeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir.叙利亚金黄地鼠中严重发热伴血小板减少综合征病毒感染的建模：STAT2在预防疾病中的重要性及法匹拉韦的有效治疗作用
J Virol. 2017 Jan 18;91(3). doi: 10.1128/JVI.01942-16. Print 2017 Feb 1.
6
Novel phlebovirus with zoonotic potential isolated from ticks, Australia.从澳大利亚蜱虫中分离出具有人畜共患病潜力的新型白蛉病毒。
Emerg Infect Dis. 2014 Jun;20(6):1040-3. doi: 10.3201/eid2006.140003.
7
Malsoor virus, a novel bat phlebovirus, is closely related to severe fever with thrombocytopenia syndrome virus and heartland virus.玛洛奥病毒，一种新型蝙蝠沙粒病毒，与发热伴血小板减少综合征病毒和“之心”病毒密切相关。
J Virol. 2014 Mar;88(6):3605-9. doi: 10.1128/JVI.02617-13. Epub 2014 Jan 3.
8
T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.T-705（法匹拉韦）在体外诱导甲型 H1N1 流感病毒产生致死性突变。
J Virol. 2013 Apr;87(7):3741-51. doi: 10.1128/JVI.02346-12. Epub 2013 Jan 16.
9
Fever with thrombocytopenia associated with a novel bunyavirus in China.中国发现一种新型布尼亚病毒所致发热伴血小板减少综合征
N Engl J Med. 2011 Apr 21;364(16):1523-32. doi: 10.1056/NEJMoa1010095. Epub 2011 Mar 16.
10
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections.T-705（法匹拉韦）及相关化合物：新型RNA病毒感染的广谱抑制剂。
Antiviral Res. 2009 Jun;82(3):95-102. doi: 10.1016/j.antiviral.2009.02.198. Epub 2009 Mar 6.